Prevention and Treatment of Regimen-Related Mucosal Toxicity

Author(s): Joanne M. Bowen .

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 2 , 2008

Become EABM
Become Reviewer

Abstract:

Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.

Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 2
Year: 2008
Page: [68 - 75]
Pages: 8
DOI: 10.2174/157489208784638802
Price: $58

Article Metrics

PDF: 2